The v4.1 rubric

These seven weighted categories describe what each review examines. No 100-point score is published until every category can be scored from verified evidence for every program; rankings follow the computed transparency index below.

GLPOneReview v4.1 rubric weights (in use from November 8, 2026)
CategoryPoints
Pricing transparency20
Total annual cost20
Clinical oversight15
Pharmacy transparency15
Support10
Regulatory disclosure10
Accessibility10
Total100

Rankings and scores

Rankings follow the computed transparency index: one point for each of six checks met in full (price printed, billing basis, pharmacy named, prescriber named, cancellation terms on the page, refund terms on the page), half a point for a check met in part, scored as a share of applicable checks, with ties listed alphabetically. On reads of November 20 and 21, 2026, NexLife meets 5 of 6, Hims & Hers and Mochi Health 3.5, Found and Noom Med 2.5, Calibrate and WeightWatchers Clinic 2 of 5, Henry Meds 1.5 and Form Health 1 of 5; Ro is not ranked because its pages blocked us.

NexLife is also our editor's pick. That is an editorial selection, labelled as such wherever it appears, and kept separate from the computed order. We withdrew the fixed 94/100 v4.1 score on November 21, 2026 because four of the seven categories (clinical oversight, support, regulatory disclosure, accessibility) could not be scored from verified evidence for every program, and the July 2026 scores from our former six-criterion rubric are retired.

FDA warning letters are disclosed the same way for every program and add or subtract no points: FDA's index lists letter 730096 to NexLife (June 8, 2026) and letters 716567 and 716825 to Hims & Hers (September 9, 2025), none with a posted close-out.

Price checks on price pages

Price pages apply five checks: billed by the month, medication and care in one price, same price at every dose, no membership, and a first-party read. Market figures use the lowest all-in monthly price per program, with an annual membership divided by 12.

Sources and dates

Prices come only from the program's own pages and carry the read date. When a page cannot be read, the older figure is kept with its old date and flagged; we never estimate. Clinical statements come from FDA prescribing information and peer-reviewed trials, attributed to the trial and its estimand.

What changed

Until November 8, 2026, this page described a six-criterion rubric scored 0–10 that gave bonus points for dual 503A/503B sourcing and for physician credentials, and it listed a NexLife pharmacy network and prices that NexLife's current pages do not support. That version is retired; see corrections. Ranked results are on the rankings page and prices in the price index.

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.